2015 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
December 8, 2015 - Edge Therapeutics to Participate in Guggenheim Securities 3rd Annual Healthcare Conference
Read More
November 20, 2015 - Edge Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Read More
November 6, 2015 - Edge Therapeutics Reports Third Quarter 2015 Financial Results
Read More
November 5, 2015 - Edge Therapeutics Names W. Bradford Middlekauff as Senior Vice President, General Counsel and Secretary
Read More
November 4, 2015 - Edge Therapeutics to Present at the 24th Annual Credit Suisse Healthcare Conference
Read More
October 12, 2015 - Edge Therapeutics Receives European Commission Orphan Drug Designation for EG-1962 in the Treatment of Patients With Subarachnoid Hemorrhage
Read More
October 6, 2015 - Edge Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option
Read More
September 30, 2015 - Edge Therapeutics Announces Pricing of Its Initial Public Offering
Read More
August 19, 2015 - Edge Therapeutics Reports Positive Top-Line Phase 1/2 NEWTON Trial Results of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Read More
May 28, 2015 - Edge Therapeutics Completes Enrollment in Phase 1/2 NEWTON Study of EG-1962 for Patients with Ruptured Brain Aneurysm
Read More
April 9, 2015 - Edge Therapeutics Raises $72.5 Million Through Successive Series C-1 and C-2 Financings
Read More
February 11, 2015 - Edge Therapeutics Reports Initial Data from its Phase 1/2 NEWTON Trial for EG-1962 for Improvement of Outcomes after Ruptured Brain Aneurysm
Read More
January 8, 2015 - Edge Therapeutics Announces Appointment of Renu Vaish, M.S. As Vice President, Regulatory Affairs
Read More

Printer Friendly Version Print PageE-mail this page Email PageRSS RSS FeedsE-mail Alerts Email AlertsView contacts IR Contacts